Your browser version is outdated. We recommend that you update your browser to the latest version.

Our Approach to efficient Cancer Immunotherapy

Our technology is a promising technology to combine with existing types of cancer treatment which includes: 

Combination with Radiotherapy

Radiotherapy is applied to 50 % of cancer patients today. Radiotherapy cause tumor cell death in the irradiated tumor. The dead tumor cells are cleared by the immune system, and in some cases activate the immune system to fight other tumors in the patient including metastasis (abscopal effect). It is well known that monocytes and other phagocytes play a major role for this mechanism, but also that these cell types are less active in cancer patients than in healthy individuals. With our technology we activate major immune cells in the cancer patients after radiotherapy to promote the abscopal effect, leading to education of the immune system to recognize, fight and eliminate metastasis in the patient.

Combination with Therapeutic Antibodies

Therapeutic Antibodies like Rituxan®, Erbitux® and Herceptin® cause tumor and stroma cell death. This effect is partly mediated through the Antibody Dependent Cell Cytotoxic effect (ADCC) and Antibody Dependent Cell Phagocytic effect (ADCP), mediated by phagocytic cells like monocytes and NK cells, and this effect is partly damaged in cancer patients. Our strategy is to enhance the ADCC and ADCP effects in cancer patients after treatment with therapeutic antibodies. 

Combination with Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors target the immune escape mechanism to promote survival of cancer patients with e.g. metastatic melanoma. A major challenge for ICI treatment is that patients with poor immune cell infiltration in the tumor are not responsive to this treatment. Our TLR7 immunotherapy can enhance immune cell infiltration in the tumors, thereby expanding the numbder of patients that can benefit from ICI treatment.